TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21981991

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 43
Study: 20347389

Group type: EXPERIMENTAL
Intervention: Valerian
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 17460697

Group type: EXPERIMENTAL
Intervention: Variant in CDKAL1 gene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Homozygous carriers of the CDKAL1 variant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Homozygotes
Number of subjects: 0
Study: 15574713

Group type: EXPERIMENTAL
Intervention: Telephone social support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nursing presence
Number of subjects: 0
Study: 11928796

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Surgical interventions (primary resection or lymphadenectomy)
Number of subjects: 52
Study: 9536449

Group type: EXPERIMENTAL
Intervention: Carbamazepine 300 mg/day
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 7633556

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of Salbutamol and Ipratropium bromide
Number of subjects: 0
Study: 31017556

Group type: EXPERIMENTAL
Intervention: Chicory seed supplementation (infused 9 g/d)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Turmeric supplementation (3 g/d)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Turmeric and chicory seed supplementation (3 g/d turmeric + infused 9 g/d chicory seed)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 28903959

Group type: EXPERIMENTAL
Intervention: High-protein breakfast
Number of subjects: 20

Group type: COMPARATOR
Intervention: High-carbohydrate breakfast
Number of subjects: 20

Group type: COMPARATOR
Intervention: High-fat breakfast
Number of subjects: 20

Group type: COMPARATOR
Intervention: High-carbohydrate and high-fat breakfasts
Number of subjects: 20
Study: 26779697

Group type: EXPERIMENTAL
Intervention: Lidocaine 1% 1 mL subcutaneously
Number of subjects: 41

Group type: COMPARATOR
Intervention: No local anesthesia (Control)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Other systemically acting analgesia
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Standard 22-gauge needle
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Smaller 25-gauge needle
Number of subjects: 41
Study: 21946541

Group type: EXPERIMENTAL
Intervention: Morning dosing of travoprost eye drops
Number of subjects: 30

Group type: COMPARATOR
Intervention: Evening dosing of travoprost eye drops
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: First month dosing of travoprost eye drops
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Second month dosing of travoprost eye drops
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Morning dosing
Number of subjects: 30

Group type: COMPARATOR
Intervention: Evening dosing
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Morning dosing vs Evening dosing
Number of subjects: 30
Study: 21252252

Group type: EXPERIMENTAL
Intervention: High-fat diet (15 En% protein, 30 En% carbohydrates, 55 En% fat)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low-fat diet (15% energy as protein, 65 En% as carbohydrates, 20 En% as fat)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 20
Study: 19148042

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (3 doses before incision, 8 hours, and 16 hours later)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Saline (3 doses before incision, 8 hours, and 16 hours later)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both groups pooled for risk factor analysis
Number of subjects: 66
Study: 18261348

Group type: EXPERIMENTAL
Intervention: Endovenous laser therapy (EVLT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saphenous veins stripping
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (EVLT and stripping)
Number of subjects: 80
Study: 14695867

Group type: EXPERIMENTAL
Intervention: Glucose Insulin intervention (maintaining euglycaemia)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Admission plasma glucose > or = 6.1 mmol/l and glycosylated haemoglobin > or = 6.2%
Number of subjects: 142

Group type: COMPARATOR
Intervention: Total series of acute stroke admissions
Number of subjects: 142
Study: 11402381

Group type: EXPERIMENTAL
Intervention: lotrafilcon A silicone hydrogel lenses (HDk; Dk = 140)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: etafilcon A hydrogel lenses (LDk; Dk = 18)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control eyes (non-lens wearing)
Number of subjects: 20
Study: 9605801

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen for 1 year
Number of subjects: 30000

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen for 2 years
Number of subjects: 30000

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen for about 5 years
Number of subjects: 30000

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen for about 5 years (node-positive)
Number of subjects: 30000

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen for about 5 years (node-negative)
Number of subjects: 30000
Study: 7809567

Group type: EXPERIMENTAL
Intervention: Bright light (about 5,000 lux) for 6 hours on the first 2 night shifts
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dark goggles during daylight
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combination of bright light plus goggles
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dim light (< 500 lux) and no goggles
Number of subjects: 50

Group type: COMPARATOR
Intervention: No goggles
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Goggles
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Larger temperature-rhythm phase shifts
Number of subjects: 50
Study: 3187466

Group type: EXPERIMENTAL
Intervention: Continuous ultrasound treatment
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo ultrasound treatment
Number of subjects: 99

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 99
Study: 4140267

Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 20
Study: 31165217

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Women and Men
Number of subjects: 106
Study: 29808377

Group type: EXPERIMENTAL
Intervention: Fosaprepitant (150 mg intravenous single dose)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control regimen (dexamethasone and ondansetron on day 1, ondansetron continuing through day 3)
Number of subjects: 1000
Study: 27976447

Group type: COMPARATOR
Intervention: Sleep restriction (4 hours)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Idealized sleep (9.5 hours)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 42
Study: 26176994

Group type: EXPERIMENTAL
Intervention: Alfentanil 56 μg/kg
Number of subjects: 84

Group type: COMPARATOR
Intervention: Alfentanil doses (0, 10, 20, 30, 40, 50, 60 μg/kg)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Thiopental 4 mg/kg and Rocuronium 0.6 mg/kg
Number of subjects: 84
Study: 23357440

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT), 16 sessions of weekly therapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 45
Study: 21458867

Group type: EXPERIMENTAL
Intervention: Desflurane (4%-6% concentration, 0.7-0.9 MAC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sevoflurane (2%-2.5% concentration, 0.7-0.9 MAC)
Number of subjects: 40
Study: 18678571

Group type: EXPERIMENTAL
Intervention: Physiotherapy-led group exercise and staff continence and mobility facilitation training
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 34
Study: 16413556

Group type: EXPERIMENTAL
Intervention: Dunaliella capsules providing 60 mg beta-carotene/day (first trial)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Dunaliella capsules (second trial)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Dunaliella capsules (in mice)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Beta-carotene-deficient Dunaliella capsules (second trial)
Number of subjects: 42
Study: 12883126

Group type: EXPERIMENTAL
Intervention: Sildenafil treatment taken as required before sexual activity, up to two times per week
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Sildenafil treatment
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Changes in sexual self-confidence and partner's wish to continue treatment
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: High pretreatment sexual desire
Number of subjects: 65
Study: 11052587

Group type: EXPERIMENTAL
Intervention: 5 mg transdermal nicotine patches
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 9206221

Group type: EXPERIMENTAL
Intervention: Phacoemulsification with small incision (6 mm) intraocular lens implantation
Number of subjects: 40
Study: 1418072

Group type: EXPERIMENTAL
Intervention: Pirenzepine (75 mg/d)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Pirenzepine (greater than 75 mg/d)
Number of subjects: 251
Study: 10269521

Group type: EXPERIMENTAL
Intervention: Group counseling (experimental group 1) with 17 patients and their spouses
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Patients participating in group counseling (experimental group 2) with 22 patients and their spouses
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group with 19 patients and their spouses who did not participate in the experimental program
Number of subjects: 58
Study: 29504820

Group type: EXPERIMENTAL
Intervention: Three-step reduction (TSR) therapy of integrated Chinese and Western Medicine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Posterior open (PO) surgery
Number of subjects: 60
Study: 29374717

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (nCRT)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 41
Study: 26758532

Group type: EXPERIMENTAL
Intervention: Discontinuation of antihypertensive medication
Number of subjects: 162

Group type: COMPARATOR
Intervention: Continuation of antihypertensive medication
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Complete discontinuation of all antihypertensive medication
Number of subjects: 162
Study: 25291923

Group type: EXPERIMENTAL
Intervention: Dedicated Education Units (DEUs)
Number of subjects: 34
Study: 21897344

Group type: EXPERIMENTAL
Intervention: Oxiplex gel (treatment group)
Number of subjects: 352
Study: 19639351

Group type: EXPERIMENTAL
Intervention: Switching to another statin
Number of subjects: 5800000

Group type: EXPERIMENTAL
Intervention: Switching more than once
Number of subjects: 5800000

Group type: COMPARATOR
Intervention: Non-switchers (continued treatment with atorvastatin)
Number of subjects: 5800000

Group type: EXPERIMENTAL
Intervention: Outpatient healthcare utilisation
Number of subjects: 5800000

Group type: EXPERIMENTAL
Intervention: Policy change
Number of subjects: 5800000
Study: 17604363

Group type: EXPERIMENTAL
Intervention: PEG‐IFN‐alpha‐2b (100 microg weekly) alone or in combination with lamivudine (100 mg daily)
Number of subjects: 70
Study: 15166128

Group type: EXPERIMENTAL
Intervention: Laparoscopic electrocautery of the ovaries followed by clomiphene citrate and rFSH if anovulation persisted
Number of subjects: 168

Group type: COMPARATOR
Intervention: Recombinant FSH (rFSH) treatment
Number of subjects: 168
Study: 11488938

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (3000 microg retinol equivalent), iron (30 mg), and folate (400 microg)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control group (iron (30 mg) and folate (400 microg))
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 203
Study: 10085700

Group type: EXPERIMENTAL
Intervention: Pruritus present in patients
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Symptoms and signs of neuropathy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Relationship between pruritus and paresthesia
Number of subjects: 51
Study: 8039405

Group type: EXPERIMENTAL
Intervention: Zofenopril calcium (7.5-30 mg twice a day)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study: 2661184

Group type: EXPERIMENTAL
Intervention: Ipriflavone (Osteofix) 600 mg/day for 6 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30733029

Group type: EXPERIMENTAL
Intervention: ACL and medial compartment reconstruction surgery (Group 1, n = 58)
Number of subjects: 112

Group type: COMPARATOR
Intervention: ACL reconstruction and nonsurgical medial compartment treatment (Group 2, n = 54)
Number of subjects: 112
Study: 30051927

Group type: EXPERIMENTAL
Intervention: Complete edentulism
Number of subjects: 4524

Group type: EXPERIMENTAL
Intervention: Partial edentulism
Number of subjects: 4524

Group type: EXPERIMENTAL
Intervention: Not having dentures
Number of subjects: 4524

Group type: EXPERIMENTAL
Intervention: Denture disuse
Number of subjects: 4524

Group type: EXPERIMENTAL
Intervention: Correlates of complete edentulism
Number of subjects: 4524

Group type: EXPERIMENTAL
Intervention: Correlates of not having dentures and denture disuse
Number of subjects: 4524

Group type: EXPERIMENTAL
Intervention: Lower than average personal income
Number of subjects: 4524
Study: 26977029

Group type: EXPERIMENTAL
Intervention: TIVA (total intravenous anaesthesia) with propofol and remifentanil
Number of subjects: 100

Group type: COMPARATOR
Intervention: CIIA (combined intravenous and inhaled anaesthesia) with sevoflurane and remifentanil
Number of subjects: 100
Study: 24085749

Group type: EXPERIMENTAL
Intervention: Nurse-community health worker intervention
Number of subjects: 268

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 268
Study: 22328192

Group type: EXPERIMENTAL
Intervention: 30 mg modified-release metoclopramide tablet every 24 h
Number of subjects: 26

Group type: COMPARATOR
Intervention: 10 mg immediate-release metoclopramide tablet every 8 h
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 30 mg modified-release metoclopramide tablet
Number of subjects: 26

Group type: COMPARATOR
Intervention: 10 mg immediate-release metoclopramide tablet
Number of subjects: 26
Study: 19760415

Group type: EXPERIMENTAL
Intervention: I-131 under rhTSH stimulus after 4-day L-T4 withdrawal
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: I-131 under rhTSH stimulus after furosemide (25 mg/day for 3 days) and 4-day L-T4 withdrawal
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: I-131 under rhTSH stimulus after furosemide (25 mg/day for 3 days) and lithium (450 mg/day for 3 days) following 4-day L-T4 withdrawal
Number of subjects: 201

Group type: COMPARATOR
Intervention: I-131 30 mCi under rhTSH stimulus without L-T4 withdrawal (control group)
Number of subjects: 201
Study: 17430318

Group type: EXPERIMENTAL
Intervention: Dopexamine (Dpx group)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN group)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of dopexamine and enteral nutrition
Number of subjects: 16
Study: 15769491

Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation (STN DBS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pre-operative group (PD patients before STN DBS)
Number of subjects: 30
Study: 11994327

Group type: EXPERIMENTAL
Intervention: Low Dose (LD) GH replacement therapy (3 microg/kg/day for 3 months, then 6 microg/kg/day for 3 months)
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Low Dose (LD) GH replacement therapy
Number of subjects: 595

Group type: COMPARATOR
Intervention: Conventional Dose (CD) GH replacement therapy (6 microg/kg/day for 3 months, then 12 microg/kg/day for 3 months)
Number of subjects: 595

Group type: COMPARATOR
Intervention: Conventional Dose (CD) GH replacement therapy
Number of subjects: 595
Study: 11692352

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% with noradrenaline 1:50,000 and vasopressin 0.25 IU/mL, and midazolam sedation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam sedation
Number of subjects: 0
Study: 7483798

Group type: EXPERIMENTAL
Intervention: Group A - three doses of 20 micrograms i.m. (n = 103)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Group B - first dose i.d. (2 micrograms), second and third doses i.m. (20 micrograms) (n = 97)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Group C - first and second doses i.d. (2 micrograms), third dose i.m. (20 micrograms) (n = 100)
Number of subjects: 300
Study: 2246786

Group type: EXPERIMENTAL
Intervention: Incentive-based smoking cessation program
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Joining the program
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Level of attendance
Number of subjects: 474
Study: 6970635

Group type: EXPERIMENTAL
Intervention: Air caloric test (60 s, 12 min, 45 degrees/29 degrees C)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Water caloric test (30 s, 30 cm3, 44 degrees/30 degrees C)
Number of subjects: 20
Study: 31180474

Group type: EXPERIMENTAL
Intervention: Home-based intervention
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Clinic-based intervention
Number of subjects: 391

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 391
Study: 29903093

Group type: EXPERIMENTAL
Intervention: BP 200 μmol/L
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: BP 400 μmol/L
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: BP 800 μmol/L
Number of subjects: 20
Study: 25552576

Group type: EXPERIMENTAL
Intervention: Exercise group (40 to 60 minutes, 3 times weekly for 6 months)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 231

Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 231
Study: 24122303

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22057944

Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate (40 mg, 1 ml)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Betametazone disodium phosphate (3 mg, 1 ml)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Triamsinolon acetonate (40 mg, 1 ml)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Serum physiological (0.09% NaCl, 1 ml)
Number of subjects: 120
Study: 19421791

Group type: EXPERIMENTAL
Intervention: Aceclofenac (100 mg) - Tizanidine (2 mg) b.i.d for 7 days
Number of subjects: 197

Group type: COMPARATOR
Intervention: Aceclofenac (100 mg) alone b.i.d for 7 days
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Aceclofenac - Tizanidine
Number of subjects: 197
Study: 17466514

Group type: EXPERIMENTAL
Intervention: Postoperative drainage (n=117)
Number of subjects: 234

Group type: COMPARATOR
Intervention: No drains (n=117)
Number of subjects: 234
Study: 15042359

Group type: EXPERIMENTAL
Intervention: Screening (AFP test and ultrasonography examination every 6 months)
Number of subjects: 18816

Group type: COMPARATOR
Intervention: Control (no screening)
Number of subjects: 18816

Group type: EXPERIMENTAL
Intervention: Screening (completed 58.2% of offered screenings)
Number of subjects: 18816
Study: 11948037

Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR) for 6 to 8 weeks
Number of subjects: 37
Study: 9616529

Group type: EXPERIMENTAL
Intervention: salmeterol 50 micrograms b.i.d.
Number of subjects: 426

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 426
Study: 7616869

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg/day continuously
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conjugated equine estrogens 0.625 mg/day combined with medroxyprogesterone acetate 5 mg/day sequentially
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both tibolone and CEE/MPA
Number of subjects: 24
Study: 2167344

Group type: EXPERIMENTAL
Intervention: Breast-feeding
Number of subjects: 176

Group type: COMPARATOR
Intervention: Bottle-feeding
Number of subjects: 176
Study: 7001490

Group type: EXPERIMENTAL
Intervention: pyritinol (800 mg daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 31141728

Group type: EXPERIMENTAL
Intervention: Sequential DL‐PDT plus IM
Number of subjects: 43

Group type: COMPARATOR
Intervention: 2 sessions of DL‐PDT
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: DL‐PDT plus IM
Number of subjects: 43
Study: 28182793

Group type: EXPERIMENTAL
Intervention: SIE (4 x 30 second Wingate sprints)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: HIIE (5 x 4 minutes at 75% Wmax)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: All exercise protocols
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CMIE (30 minutes at 50% of Wmax)
Number of subjects: 8
Study: 26426836

Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Number of subjects: 579

Group type: COMPARATOR
Intervention: High-Definition White Light Endoscopy (HD-WLE)
Number of subjects: 579
Study: 23374411

Group type: EXPERIMENTAL
Intervention: SU-TEm: etch‐and‐rinse + moist dentin
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: SU-TEd: etch‐and‐rinse + dry dentin
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: SU-SEet: selective enamel etching
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: SU-SE: self‐etch
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: SU-SE
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: SU-TEm
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: SU-TEd
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: SU-SEet
Number of subjects: 39
Study: 17542150

Group type: EXPERIMENTAL
Intervention: Apricitabine (ATC) 1,200 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Apricitabine (ATC) 1,600 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15581204

Group type: EXPERIMENTAL
Intervention: Mycobacterium vaccae (SRL172) immunotherapy
Number of subjects: 1018

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1018